- cafead Aug 30, 2024 at 11:22: AM
via Two months ago, Alnylam Pharmaceuticals revealed that a medicine it’s been developing for people with a deadly heart condition succeeded in a closely watched clinical trial.
On Friday, the biotechnology company is presenting fuller study findings its leaders claim are evidence the drug should become the new standard of care for the disease, called transthyretin amyloidosis cardiomyopathy.
article source
On Friday, the biotechnology company is presenting fuller study findings its leaders claim are evidence the drug should become the new standard of care for the disease, called transthyretin amyloidosis cardiomyopathy.
article source